Study Description: This 11 week study will be conducted in subjects with a clinical diagnosis of sporadic ALS. The primary study objective is to determine whether treatment with mexiletine, an FDA approved medication for abnormal heart rhythms, will reduce cortical hyperexcitability (over active, excited cells). The hope is that this may be able to slow the disease progression in ALS.
Principal Investigator: Michael Rivner
Eligibility Criteria: Inclusion: Diagnoses of sporadic ALS, with symptom onset ? 60 months prior to screening visit Slow vital capacity (SVC) ? 50% and must be able to swallow pills. Exclusion: Known history of epilepsy, congestive heart failure or myocardial infarction within the past 24 months. Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine
Compensation: No, subjects will not be compensated.
If you don't see specific studies that interest you, please submit your contact information for future studies.